HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintains a $38 price target.
June 12, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reiterates Buy rating on Protagonist Therapeutics and maintains a $38 price target.
The reiteration of the Buy rating and maintenance of the $38 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Protagonist Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100